Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.68% | -3.35% | -34.43% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Bearish | Neutral |
Resistance | 43.60 | 56.84 | 91.10 |
Spread/Res. | -9.98% | -30.95% | -56.92% |
Spread/Supp. | -1.08% | -1.08% | +60.01% |
Support | 39.68 | 39.68 | 24.53 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- APLS Stock
- Charts Apellis Pharmaceuticals, Inc.